Inside Drug Pricing

CMS Will Drop Three Part D Drugs From IRA Pricing Program In 2027

By Gabrielle Wanneh / December 1, 2025 at 7:26 PM

Lower prices for three expensive Medicare Part D drugs that underwent price negotiations in Medicare will not be effective for those drugs beginning in 2027, as the drugs will be removed from the negotiation program due to the introduction of bona fide generic and biosimilar competition, CMS reportedly announced in a memo last month.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Inside Drug Pricing

CMS Will Drop Three Part D Drugs From IRA Pricing Program In 2027

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.